Showing 271-280 of 337 results for "".
- Topline Phase 2b Data Promising for Timber's Topical Isotretinoin in CIhttps://practicaldermatology.com/news/topline-phase-2b-data-promising-for-timbers-topical-isotretinoin-in-ci/2460946/Top-line data from Timber Pharmaceuticals’ Phase 2b CONTROL study show “clinically meaningful efficacy with a favorable safety profile” for investigational topical isotretinoin, says the company’s Chairman and CEO John Koconis. TMB-001 is formulated using
- ASA Honors Outstanding Researchershttps://practicaldermatology.com/news/asa-honors-outstanding-researchers/2460029/Luis Diaz, MD of the University of North Carolina, Chapel Hill and John Stanley, MD of the University of Pennsylvania took home the American Skin Association’s David Martin Carter Mentor Award at the Annual Meeting of t
- Experimental Drug May Reverse Hair Loss, Hair Whitening and Skin Inflammationhttps://practicaldermatology.com/news/experimental-drug-may-reverse-hair-loss-hair-whitening-and-skin-inflammation/2457669/An experimental drug can successfully reverse hair loss, hair whitening and skin inflammation linked by previous studies to human diets heavy in fat and cholesterol, according to a new Johns Hopkins study in mice. The investigators say the compound halts the production of glycosphingolipi
- Study: Increased Risk of Uterine Fibroids Seen in African-American Women with CCCAhttps://practicaldermatology.com/news/study-increased-risk-of-uterine-fibroids-seen-in-african-american-women-with-ccca/2457944/African-American women with central centrifugal cicatricial alopecia (CCCA) have an increased chance of developing uterine fibroids, a new study suggests. The study, which appears in the December 27 issue of JAMA Dermatology, analyzed patient data from the Johns Hopkins electroni
- Is a Topical Gel Made From Oral Blood Pressure Drugs a Panacea for Wound Healing, Wrinkles and More?https://practicaldermatology.com/news/is-a-topical-gel-made-from-oral-blood-pressure-drugs-a-panacea-for-wound-healing-wrinkles-and-more/2457989/Topical gel made from angiotensin II receptor blockers may speed the healing of chronic skin wounds in mice and pigs, Johns Hopkins researchers report. The findings, published in the Journal of Investigative Dermatology, marks efforts to seek approval from the U.S. Food and Drug
- Maria Carell Named New CEO of Revision Skincare LLC, Goodier Cosmetics LLChttps://practicaldermatology.com/news/maria-carell-named-new-ceo-of-revision-skincare-llc-goodier-cosmetics-llc/2458223/Maria Carell is the new CEO of Revision Skincare® LLC and Goodier Cosmetics LLC. Ms. Carell's appointment follows the retirement of John Muller, the company's founder. Mr. Muller will retain hi
- Researchers Discover New Antibiotic That May Fight MRSAhttps://practicaldermatology.com/news/researchers-discover-new-antibiotic-that-may-fight-mrsa/2458282/Researchers at the University of East Anglia (UEA) and the John Innes Centre (JIC) have uncovered a new antibiotic that they say is potent against antibiotic-resistant ‘superbugs’ like methicillin resistant Staphylococcus aureus (MRSA). The researchers isolated
- Merz North America Appoints New Chief Financial Officerhttps://practicaldermatology.com/news/20130807-merz_north_america_appoints_new_chief_financial_officer/2459482/Merz North America has appointed John Donofrio as Chief Financial Officer and Head of Business Development - North America. In this role, Donofrio will be primarily accountable for financial performance, cost management, and strategic business planning and analysis for the Finance organization in No
- TURO SKIN System Launchedhttps://practicaldermatology.com/news/20121018-turo_skin_system_launched/2459701/Founder and CEO John Renucci, MD, created TURO SKIN, a simplified skincare system for men, which has now been released. The collection offers solutions for face, shave, hair, and body. TURO SKIN products are available online at www.turoskin.com an
- Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeuticshttps://practicaldermatology.com/news/Johnson-johnson-completes-acquisition-yellow-jersey-therapeutics/2467362/Johnson & Johnson has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody being evaluated for the treatment of atopic dermatitis